Related Research Articles
Dana–Farber Cancer Institute is a comprehensive cancer treatment and research institution in Boston, Massachusetts. Dana-Farber is the founding member of Dana–Farber/Harvard Cancer Center, Harvard's Comprehensive Cancer Center designated by the National Cancer Institute, and one of the 15 clinical affiliates and research institutes of Harvard Medical School.
Emil "Tom" Frei III was an American physician and oncologist. He was the former director and former physician-in-chief of the Dana-Farber Cancer Institute in Boston, Massachusetts. He was also the Richard and Susan Smith Distinguished Professor of Medicine at Harvard Medical School.
Olufunmilayo I. Olopade is a hematology oncologist, Associate Dean for Global Health and Walter L. Palmer Distinguished Service Professor in Medicine and Human Genetics at the University of Chicago. She also serves as director of the University of Chicago Hospital's Cancer Risk Clinic.
Alan D. D'Andrea is an American cancer researcher and the Fuller American Cancer Society Professor of Radiation Oncology at Harvard Medical School. D'Andrea's research at the Dana Farber Cancer Institute focuses on chromosome instability and cancer susceptibility. He is currently the director of the Center for DNA Damage and Repair and the director of the Susan F. Smith Center for Women's Cancer.
Kenneth Offit is an American cancer geneticist and oncologist. He is currently Chief of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center, a member of the Program in Cancer Biology and Genetics at the Sloan-Kettering Institute, and Professor of Medicine and Healthcare Policy and Research at Weill Cornell Medical College. He is also a member of both the Board of Scientific Counselors of the National Cancer Institute and the Evaluation of Genomic Applications in Practice and Prevention working group of the U.S. Centers for Disease Control. In 2016, he was elected as a Member of the National Academy of Medicine. In 2018, he was named a Fellow of the American Society of Clinical Oncology.
Edward J. Benz Jr. is the former president of Dana-Farber Cancer Institute in Boston, Massachusetts., and the Richard and Susan Smith Professor of Medicine as well as a professor of genetics at Harvard Medical School.
Waun Ki Hong was Professor of Medicine at The University of Texas MD Anderson Cancer Center, where he served as chairman of the Department of Thoracic/Head & Neck Medical Oncology from 1993 to 2005 and as head of the Division of Cancer Medicine from 2001 to 2014. He was also an American Cancer Society Professor and the Samsung Distinguished University Chair in Cancer Medicine emeritus.
William G. Kaelin Jr. is an American Nobel Laureate physician-scientist. He is a professor of medicine at Harvard University and the Dana-Farber Cancer Institute. His laboratory studies tumor suppressor proteins. In 2016, Kaelin received the Albert Lasker Award for Basic Medical Research and the AACR Princess Takamatsu Award. He also won the Nobel Prize in Physiology or Medicine in 2019 along with Peter J. Ratcliffe and Gregg L. Semenza.
Michael A. Caligiuri, M.D. is a physician scientist focused on oncology and immunology. He is currently the president of the City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief Distinguished Chair. He was elected president of the American Association for Cancer Research, the world's largest cancer research organization, for 2017–2018.
David M. Livingston was the Deputy Director of the Dana-Farber/Harvard Cancer Center, Emil Frei Professor of Genetics and Medicine at Harvard Medical School, Chairman of the Executive Committee for Research at Dana-Farber Cancer Institute. Dr. Livingston joined the Harvard faculty in 1973. His research focused on breast and ovarian cancer.
Kenneth C. Anderson is an American hematologist-oncologist and cancer researcher who is primarily known for advances in the treatment of multiple myeloma. He directs the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute and is the Kraft Family Professor of Medicine and Vice Chair of the Joint Program in Transfusion Medicine at Harvard Medical School.
Carlos L. Arteaga is the Associate Director for Clinical Research, director of the Center for Cancer Targeted Therapies, and professor of Cancer Biology and Medicine at Vanderbilt-Ingram Cancer Center. In 2014–2015, he was the president of the American Association for Cancer Research.
Daniel D. Von Hoff is the physician in chief and director of translational research at Translational Genomics Research Institute (TGen). He is also a professor of medicine at the Mayo Clinic and medical director of research as well as chief scientific officer at US Oncology. He is most notable for his work in targeted therapies for the treatment of cancer. He led the development of gemcitabine, and has several drugs in development.
Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy.
Kornelia Polyak is a professor of medicine at Harvard Medical School and an internationally recognized breast cancer expert.
Ann Hart Partridge is an American medical oncologist. She is the founder and director of the Young and Strong Program for Young Women with Breast Cancer at the Susan F. Smith Center for Women's Cancers at the Dana–Farber Cancer Institute.
Scott Allen Armstrong is an American pediatric oncologist. Armstrong and his team were the first to isolate rare leukemia stem cells in a mouse model of leukemia.
Levi A. Garraway is an American oncologist. His research team was among the first to adapt genomics technologies to enable scalable, high-throughput clinical approaches to cancer gene mutation profiling. As a result, he was inducted into the American Society for Clinical Investigation, American Association for Cancer Research, and National Academy of Medicine.
Monica Bertagnolli is an American surgical oncologist at Dana–Farber Cancer Institute and the Richard E. Wilson Professor of Surgery at Harvard Medical School. She advocates for inclusion of rural communities in clinical studies and serves as Chair of the Alliance for Clinical Trials in Oncology. Bertagnolli specializes in the treatment of tumors from gastrointestinal diseases. She is the former President of the American Society of Clinical Oncology and was elected Fellow of the National Academy of Medicine in 2021.
Benjamin Levine Ebert is the Chair of Medical Oncology at the Dana–Farber Cancer Institute and the George P. Canellos, MD and Jean S. Canellos Professor of Medicine at Harvard Medical School.
References
- 1 2 3 4 "Judy E. Garber, MD, MPH". www.aacr.org. Retrieved 17 January 2019.
- ↑ "Judy E. Garber, MD, MPH - Dana-Farber Cancer Institute | Boston, MA". www.dana-farber.org. Retrieved 17 January 2019.
- 1 2 "Judy E. Garber | Researcher". Breast Cancer Research Foundation. 18 June 2014. Retrieved 17 January 2019.
- ↑ "Breast Cancer Research Foundation". Breast Cancer Research Foundation.
- ↑ "The American Society for Clinical Investigation" . Retrieved 17 January 2019.